NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

2005;105:642-643. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15738038 .

571. Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast 2004;13:97-103. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15019688 . 572. Haagensen CD. Inflammatory Carcinoma. Diseases of the Breast. Philadelphia: WB Saunders; 1956:488-498. 573. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 2007;110:1436-1444. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17694554 . 574. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 2005;23:1941-1950. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15774787 . 575. Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 2011;117:1819-1826. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21509759 . 576. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-975. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15998949 . 577. Li J, Gonzalez-Angulo AM, Allen PK, et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 2011;16:1675-1683. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22147002 . 578. Dawood S, Broglio K, Gong Y, et al. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008;112:1905-1911. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18300243 .

564. Witzel ID, Müller V, Harps E, et al. Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 2008;19:191-192. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18084047 . 565. Kelly H, Graham M, Humes E, et al. Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer 2006;7:339-341. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17092403 . 566. Dawood, S, Cristofanilli M. What progress have we made in managing inflammatory breast cancer? Oncology 2007;21:673-679. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17564325 567. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-1024. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1588366 . 568. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005;65:2170-2178. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15781628 . 569. Van Laere SJ, Van den Eynden GG, Van der Auwera I, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006;95:243-255. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16261404 . 570. Zell JA, Tsang WY, Taylor TH, et al. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009;11:R9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19228416 .

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-108